Novartis signs drug delivery agreement with Alteogen

Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen’s ALT-B4 technology. The agreement includes option exercise fees, milestone payments, and royalties on net sales of products commercialised with ALT-B4 technology. The deal allows Novartis options for exclusive global rights to develop subcutaneous versions of products using ALT-B4. Credit: Michael Derrer Fuchs/Shutterstock.com. Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen’s ALT-B4 technology. The deal allows Novartis to exercise…

Salong Debbarma · 2026-09-03

Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen’s ALT-B4 technology.

Source: Pharmaceutical Technology